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The concept of the CNS as an immune-privileged organ has led to a common misunderstanding that it is not
an active immunological organ, guarded from its surroundings by the blood-brain barrier (BBB). Recent
advances in this field clearly demonstrate that theCNS is a highly immunologically active organ, with complex
immune responses mostly based on innate immune processes. Such responses implicate a continuum of
heterogeneous cell types both inside the CNS, in the periphery, and at their interface, the BBB. This Review
aims to discuss the importance of the BBB as the first line of defense against brain infections and injuries of
the CNS and themainmolecular mechanisms involved in the control of the innate immune system of the CNS.
We also review the central role of the neurovascular unit in diseases of the CNS and how it can be targeted for
novel therapeutic strategies.Introduction
The CNS is a complex organ, to say the least. Numerous cell
types act in accord to maintain its integrity and its functions,
separated into three main groups: neurons, the glia, and endo-
thelial cells. Previously thought to be outnumbered 10:1, new
data estimate that neurons are present in equal proportion to
glial cells across the CNS, although this ratio is highly variable,
depending on the region studied (Azevedo et al., 2009). A clear
count of the number of endothelial cells across the CNS has
not been reported, although it was shown that endothelial cells
and neurons are present in similar amounts in the amygdaloid
complex (Garcı´a-Amado and Prensa, 2012). In any case, neu-
rons, glial cells, and endothelial cells exist in close proximity of
each other, forming the neurovascular unit (NVU), a coherent
view of the CNS as a whole instead of a blend of compartmental-
ized cell types (Zlokovic, 2008).When it comes to its defense, the
CNS also has highly peculiar specificities. Devoid of a lymphatic
system, its integrity is guarded exclusively through an innate
immune system with an adaptive immunity only present in spe-
cific conditions (Rivest, 2009). The term ‘‘immune privilege’’
has often been used to describe the defenses of the CNS. While
it is true that specific responses are in place in this organ, the
same can be said for every organ in the body. For instance,
the lungs respond to a given insult in a specific way that might
not be as efficient as in the spleen. In a way, every organ in the
body is immune privileged. Such a term also suggests that
immune processes are not as important in the CNS as in other
organs. The innate immune system, however, is highly active in
the CNS, organizing a complex response involving every cell
type present.
Another concept regarding the integrity of the CNS that needs
to be tackled is that, in normal physiology, the blood-brain barrier
(BBB) is a hermetic wall shielding the CNS from any outside con-
tacts. However, the BBB is actually a tightly controlled mem-214 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.brane through which active transport is organized and plays a
central role in the control of innate immune responses. We will
strive in this Review to highlight the importance and frequency
of immune responses in the CNS and also to show the need of
seeing such responses as a continuous crosstalk between
numerous cell types in the CNS and the periphery, not as a linear
event. The CNS is not an island separated from the rest of the
body but rather an integral member of it, in constant link with
its environment.
The Blood-Brain Barrier
In humans, one-fifth of the body’s total energy consumption
takes place in the CNS. It is therefore an excessively vascular-
ized organ for the efficient intake of oxygen and nutrients. In con-
stant and close contact with neurons, the BBB is one of the most
important sites for the control of the CNS microenvironment and
homeostasis. As such, the BBB fulfills two main functions: a
physical barrier and a selective exchange barrier. While the
BBB has long been seen as a staunch wall guarding the CNS,
recent evidence demonstrates that this barrier is a lot more plas-
tic and adaptive than was first assumed.
The First Line of Defense
TheBBBmechanically separates theCNS from the circulation by
the presence of specialized endothelial cells tightly attached to
each other via tight junctions (TJs) and adherens junctions
(AJs) (Hermann and Elali, 2012; Hawkins and Davis, 2005). TJs
are formed by transmembrane proteins such as occludin, clau-
dins, and junctional adhesion molecules (JAMs). AJs, on the
other hand, are constituted by the single-pass transmembrane
glycoprotein cadherins such as cadherin-E, cadherin-P, and
cadherin-N (Schulze and Firth, 1993; Takeichi, 1995). The role
for these junctions is to restrict and prevent blood-borne mole-
cules and peripheral cells from entering the CNS (Wilson et al.,
2010; Pardridge, 2003). The presence of these TJs also gives
Figure 1. The Role of the Blood-Brain
Barrier as a Physical and Selective
Exchange Barrier
The blood-brain barrier (BBB) maintains an
adequate microenvironment for optimal neuronal
function due to its physical and selective ex-
change characteristics. The presence of tight
junctions (TJs) and adherens junctions (AJs)
among brain endothelial cells is the main physical
property of the BBB.
(A) TJs are formed by transmembrane proteins,
i.e., occludin, claudins, and junctional adherens
molecules (JAMs), that interact with cytosolic
adaptor proteins, i.e., guanylate kinase-like pro-
teins (MAGUKs, i.e., zonula occludens [ZO]1, ZO2
and ZO3), cingulin, afadin (AF6), and 7H6, which
act as scaffolds for the transmembrane proteins
and connectors of TJs to the cytoskeleton. TJ
formation induces polarization of brain endothelial
cells and the formation of endothelial membranes
with luminal (facing blood circulation) and ablu-
minal (facing brain parenchyma) sides. AJs are
formed by the transmembrane glycoprotein VE-
cadherin that interacts with cytosolic adaptor
proteins, i.e., a-, b-, g- and p120 catenin, and
the platelet endothelial cell adhesion molecule-1
(PECAM-1) homophilic interaction with adjacent
proteins. The selective exchange characteristics
are due to the presence of sophisticated active
transport mechanisms, such as ABC transporters,
i.e., ABCB1, ABCG2 (endothelial luminal side), and
ABCC1 (endothelial abluminal side), water chan-
nels, i.e., AQP4 (astrocyte endfeet), and solute
carriers, i.e., Glut-1 (both endothelial luminal and
abluminal sides).
(B) Although tight and highly selective, several
molecules and cells can still cross the BBB under
physiological and pathophysiological conditions
by using several narrowly controlled routes, such
as (1) receptor-mediated endocytosis route, i.e.,
transferrin receptor, insulin receptor, and LRP-1;
(2) diffusion route for hydrophilic low molecular
weight molecules that can be used by immune
cells, bacteria, and viruses to infiltrate into the
CNS; and (3) the nonspecific endocytosis route,
i.e., fluid-phase and adsorptive endocytosis,
which can be hijacked by immune cells, bacteria,
and viruses to enter brain parenchyma. EC,
endothelial cells; P, pericytes; A, astrocyte end-
feet; M, microglia.
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distinct sides: the luminal side facing the circulation and the
abluminal side facing the CNS parenchyma (Figure 1A). While
the cerebral endothelial cells of the luminal side interact
intensively with bioactive molecules and immune cells in the
circulation, the abluminal side interacts with the basal lamina:
extracellular matrix proteins (EMPs), bioactive molecules (cyto-
kines, growth factors, etc.), and cells of the parenchyma (Her-
mann and Elali, 2012). The deregulation of TJs and AJs is central
in innate immune responses of theCNS. They are highly sensitive
to major cytokines produced during such a response such as
Tumor Necrosis Factor a (TNF-a), Interleukin-1b (IL-1b), and
IL-6 (Minagar and Alexander, 2003; Duchini et al., 1996).
The BBB is also the interface between the CNS and the circu-
lation, tasked with maintaining an adequate microenvironment
for optimal neuronal function. Therefore, the permeability of thebarrier is complemented by a number of sophisticated methods
of transport that selectively control the exchange between CNS
parenchyma and blood circulation. The BBB restricts the pas-
sage of toxic peptides into the CNS, among which is amyloid-b
(Ab) (Mackic et al., 2002). In parallel, it tightly controls the
passage of other peptides required for neuronal function, via
specialized peptide carriers expressed in the BBB (Deane
et al., 2008; Zlokovic et al., 1987). These include ion channels,
water channels, pumps, membrane receptors, carriers, and
transporters. Ion channels such as Kir4.1 control the gradients
of numerous crucial electrolytes for optimal neuronal functions
(K+, Na+, Ca2+, etc.) (Butt and Kalsi, 2006), while water channels,
mainly Aquaporin 4, evacuate the water produced by glucose
metabolism (Amiry-Moghaddam and Ottersen, 2003). Although
cerebral endothelial cells exhibit low endocytosis activity, selec-
tive and tightly controlled trans-cellular transport mechanismsNeuron 78, April 24, 2013 ª2013 Elsevier Inc. 215
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endocytosis. Nonspecific endocytosis includes fluid-phase
endocytosis (the capture of soluble molecules by endothelial
membrane vesicles) and adsorptive endocytosis (binding of
molecules by endothelial membrane proteins) (Gloor et al.,
2001). Receptor-mediated endocytosis involves endothelial
transmembrane receptors, such as the transferrin receptor
(Zheng and Monnot, 2012), the insulin receptor (Banks et al.,
2012), and the low-density lipoprotein (LDL) receptor-related
proteins (LRPs), namely LRP-1 (Deane et al., 2008). The family
of ATP-binding cassette (ABC) transporters also plays a central
role as efflux transporters for a wide range of lipophilic and
amphipathic natural products, among which are bacterial,
herbal, and fungal toxins. They act as a detoxification system
by protecting neurons from toxic compounds present in their
microenvironment (ElAli and Hermann, 2011). The drug trans-
porters ABCB1 and ABCG2 have been shown to be highly
expressed at the luminal side of endothelial cells, acting as gate-
keepers by impeding toxic compounds from CNS entry and
accumulation (Figure 1B).
Entry of Immune Cells into the CNS
For decades, the immune privilege of the CNS was understood
as an absence of an immune system inside the CNS, and the
BBB was considered only as a barrier isolating the CNS from
the peripheral immune system, preventing the entry of infectious
agents and immune cells into the CNS (Pachter et al., 2003).
Extensive work in the last decade unravelled the presence of a
specialized intrinsic innate immune system in the CNS (Rivest,
2009), which was accompanied by several observations
showing that the BBB is not a neutral and passive barrier, from
an immunological point of view, but rather contributes actively
to the immune response of the CNS (Muldoon et al., 2013).
More precisely, several data sets showed that the peripheral
immune cells can still cross an intact BBB (Carson et al.,
2006), and the latter can modulate the function and control the
fate of infiltrating cells (Ifergan et al., 2008), outlining a more
active role of the BBB in the CNS intrinsic innate immunity. While
there is limited infiltration of peripheral immune cells into the CNS
in physiological conditions, neutrophils, eosinophils, T lympho-
cytes, monocytes, and others can be found in the CNS paren-
chyma after injuries to the CNS, including infections and chronic
diseases such as multiple sclerosis (MS) (Wilson et al., 2010).
However, the luminal side of the BBB is in constant contact
with leukocytes patrolling the barrier. The advent of in vivo imag-
ing techniques such as two-photon microscopy has allowed for
the live imaging of cells constantly patrolling the brain vascula-
ture (Coisne et al., 2013) and to better understand the impor-
tance of such a mechanism (Shechter and Schwartz, 2013).
Immune surveillance of the BBB is critical for the organism to
respond to threats to the CNS. Leukocytes in the circulation
bind endothelial cells of the BBB through adhesion molecules
such as VCAM-1 and ICAM-1, sensing for distress signals from
the CNS. Such a signal may be mediated via chemokines and
cytokines released by microglia, astrocytes, and pericytes
(Takeshita and Ransohoff, 2012). The exact mechanisms of
transmigration into the CNS are still unknown, although it is
believed to occur by paracellular means, implying a loosening216 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.of the TJ between endothelial cells of the BBB (Sagar et al.,
2012). While detrimental in certain pathological cases such as
multiple sclerosis, the recruitment of leukocytes into the CNS
can play a beneficial role to help resident microglia in resolving
certain insults (Simard et al., 2006) or even in gene therapy re-
placements (Cartier et al., 2009).
The Point of Entry for Pathogens into the CNS
The BBB, however, is not without fault. Under constant attack by
pathogens, tightly regulated processes can become detrimental
and actually contribute to the development of an infection.
Pathogens enter into the CNS either by paracellular (between
endothelial cells) or by trans-cellular (through them) mechanisms
(Ley et al., 2007; Bencurova et al., 2011). As a basic first line of
defense, TJs are challenged by some infectious agents in order
to weaken the physical properties of the BBB and infiltrate the
CNS. The viral glycoprotein gp120 of HIV has been shown to
breach the BBB by activating the chemokine receptors C-C che-
mokine receptor type 5 (CCR5) and C-X-C chemokine receptor
type 4 (CXCR4) (Kanmogne et al., 2005; Andra´s et al., 2005),
resulting in TJ protein proteolytic degradation via proteasome
(Nakamuta et al., 2008; Wang et al., 2011). On the other hand,
the meningococcal type IV pili bacteria have been reported to
infiltrate into the CNS by recruiting the polarity complex Par3/
Par6/PKCzeta that governs TJ formation at the luminal side of
the BBB. This results in the formation of ectopic intercellular
junctional domains at the site of bacteria-cerebral endothelial
cell interaction, depleting TJ proteins and consequently breach-
ing the BBB (Coureuil et al., 2009). Moreover, these bacteria can
take advantage of the biased b2-adrenoceptor/b-arrestin
signaling pathway in endothelial cells in order to tightly adhere
to the luminal side of BBB and to delocalize TJ proteins, thus
creating anatomical gaps through the BBB that bacteria can
use to infiltrate into the CNS (Coureuil et al., 2010). Transport
mechanisms can also be used to trick cerebral endothelial cells
into letting infectious agents cross the BBB. The adsorptive
endocytosis takes place when glycoproteins in cerebral endo-
thelial cell membrane bind other glycoprotein ligands in a
lectin-like fashion. The internalized materials can be trafficked
and transported either to lysosomes, to theGolgi complex/endo-
plasmic reticulum, or to the opposite cell membrane (Banks and
Broadwell, 1994). As cerebral endothelial cells do not express
CD4 and galactosylceramide (Moses et al., 1993), HIV-1 and
HIV-infected immune cells use other routes to invade CNS
parenchyma by using their own cell surface glycoproteins to
engage the adsorptive endocytosis mechanism on cerebral
endothelial cells in order to cross over the barrier formed by
these cells, thus infiltrating and infecting the CNS (Banks et al.,
1997). Moreover, the poliovirus (PV) has been shown to cross
the BBB via two mechanisms, either by exploiting the recep-
tor-mediated endocytosis via the CD155 receptor (i.e., PV
receptor, PVR) or by inducing caveolin-dependent endocytic
mechanism at cerebral endothelial cells (Coyne et al., 2007).
Moreover, it has been proposed that BBB breakdown could
contribute to epilepsy pathogenesis. As such, BBB failure has
been proposed to take place early in epilepsy pathogenesis,
which causes the entry of blood-borne molecules into the brain,
namely albumin (van Vliet et al., 2007). Albumin extravasation
Figure 2. Molecular Control of Innate Immune Responses by Pattern Recognition Receptors
Pattern recognition receptors (PRRs) recognize various parts of a pathogen to induce a number of signaling pathways centering mostly around adaptor proteins
Myd88 and TRIF in order to stimulate transcription factors NF-kB or IRF3, respectively. These control the release of specific cytokines to attack the pathogen.
Another level of control of the innate immune response is at the level of the inflammasome, a multiprotein complex centered around the activation of caspase 1,
which produces active mature inflammatory cytokines IL-1b and IL-18 from their precursors. The pathway presented here is a simplified version of a much more
complex pathway, a thorough discussion of which can be found in the literature (Kumar et al., 2011).
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growth factor b (TGFb)-receptor II (TGFb-RII), therefore exacer-
bating BBB dysfunction and initiating epileptic activity and sei-
zures (Friedman et al., 2009). This epileptic activity has been sug-
gested to induce long-lasting innate immunity response and to
promote infiltration of lymphocytes into the brain (Vezzani, 2005).
Innate Immune Responses in the CNS
A complex immune reaction is engaged in the CNS in response
to mechanical or ischemic traumas, viral or bacterial infections,
or the accumulation toxic proteins. We discuss here the molec-
ular bases of the innate immune response in the CNS.
Pattern Recognition Receptors and the Control of the
Innate Immune System
In cases of infections, traumas, and pathological conditions, the
CNS comes into contact with small protein patterns that regulate
innate immunity, found in large numbers of microorganisms
(Figure 2). Such patterns (coined PAMPs for pathogen-associ-
ated molecular patterns and DAMPS for danger-associated
molecular patterns) include proteins from bacterial membranes
such as peptidoglycans, intracellular proteins such as heat-shock proteins, and nonprotein products such as ATP and
urea and nucleic acid patterns such as nonmethylated CpG-
containing DNA, dsRNA, and ssRNA (Kumar et al., 2011). These
are recognized by pattern recognition receptors (PRRs), of which
three major families exist: Toll-like receptors (TLRs), Nod-like
receptors (NLRs), and RIG1-like receptors (RLRs). The role for
these receptors in the CNS has beenmostly studied in microglia,
but astrocytes, oligodendrocytes, endothelial cells, and even
neurons express functional levels of some of these receptors
(Hanamsagar et al., 2012). The engagement of such receptors
results in the induction of specific pathways and the release of
specific cytokines that play a role in resolving the injury. There
are 11 TLR family members in humans and 13 in mice. A role
for TLR1-9 has been described in the CNS and, while mostly
active in microglia, TLRs are also found in neurons, astrocytes,
and endothelial cells. TLRs can act alone or heterodimerize to
create specific responses to a given stimuli. All TLRs except
TLR3 signal through the adaptive protein Myd88, which leads
to the induction of NF-kB and the release of cytokines, such
as IL-1b, TNF-a, and IL-12. Conversely, TLR3 cannot activate
Myd88 but signals through a TRIF-dependent pathway, leadingNeuron 78, April 24, 2013 ª2013 Elsevier Inc. 217
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such as IFNb. TLR4 can also signal through TRIF with the help
of the adaptor protein TRAM. Both Myd88 and TRIF-dependent
signaling pathways can also engagemitogen-associated protein
kinase (MAPK) pathways, including ERK1/2, p38, and JNK,
which lead to the stimulation of cell growth and the induction
of inflammatory cytokine production (Brown et al., 2011). For
an in-depth review of TLR pathways, the reader can consult
Hanke and Kielian (2011) and Rivest (2009).
A function for NLRs in neuroinflammation is a rather recent dis-
covery. Mostly known for their functions in the spleen and lymph
nodes, there ismuch still to learn of their roles in the CNS. Among
the 21 members of the NLR family, NLRP1-3, NLRP6, NLRP10,
NOD1, and NOD2 show the highest level of expression in the
CNS, mostly in microglia but also in astrocytes, oligodendro-
cytes, neurons, and endothelial cells for some subtypes (Rose-
nzweig et al., 2011). Among these, NLRP3 and NOD2 have
been the most studied so far because of their implication in
autoinflammatory diseases of the CNS (Deane et al., 2012).
NOD2 can respond to muramyl dipeptide (MDP, a PAMP from
bacterial cell walls) and viral ssRNA (Ribes et al., 2012). NOD2
activates NF-kB transcription through the adaptor protein
RICK, which leads to the production of proinflammatory cyto-
kines in response to MDP (Ribes et al., 2012). In response to viral
ssRNA, NOD2 activates the IRF3 transcription factor with the
MAVS adaptor protein, leading to the release of type 1 inter-
ferons (Strober and Watanabe, 2011). NLRP3 is normally in a
repressed state, bound to specific chaperone proteins. The
presence of an array of different signals can liberate and there-
fore activate NLRP3. Such signals include PAMPs, DAMPs,
and intact pathogens (Zambetti et al., 2012). Upon its release,
NLRP3 activates the inflammasome, a complex of proteins
that includes caspase-1, leading to the release of active IL-1b
from a precursor (Zambetti et al., 2012).
The final type of pattern recognition receptors, RIG-1-like
receptors, is geared toward the recognition of viral nucleic acids
in the cytoplasm (Creagh and O’Neill, 2006). Three members of
this family have been described so far: retinoic acid-induced
gene 1 (RIG-1), melanoma differentiation-associated gene 5
(MDA5), and laboratory of genetics and physiology 2 (LGP2).
Acting similarly to some NLRs, RLRs recruit adaptor molecule
MAVS and TRAF or the inflammasome to induce both IRF3
and NF-kB transcription, leading to the release of type 1 inter-
ferons and proinflammatory cytokines with antiviral properties,
such as IL-1b and IL-18 (Yoneyama and Fujita, 2010). All three
members are expressed in the brain, with higher levels detected
for LGP2 and RIG-1 by real-time PCR (Lech et al., 2010). There is
much still to learn regarding the role of RLRs in the brain, but both
RIG-1 andMDA5were shown to be implicated in the response to
vesicular stomatitis virus (Furr et al., 2008), the West Nile virus
(Daffis et al., 2008), and others. Both MDA5 and RIG-1 are ex-
pressed mostly by microglia and astrocytes (Chauhan et al.,
2010) but also by neurons in which they contribute to the innate
immune response to pathogens (Peltier et al., 2010).
Endpoint of the Innate Immune System: Cytokines and
Phagocytosis
The engagement of PRRs converges on NF-kB and/or IRF3 to
induce the expression of cytokines (IL-1b, IL-6, TNFa, IL-18,218 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.IL-12, IFNb, TGFb, etc.), chemokines (MIP-1a, MCP-1, RANTES,
etc.), reactive oxygen species (ROS), and free radicals.
Describing the effects and roles of each cytokine is beyond the
scope of this Review, as excellent Reviews on the subject can
be found in the literature (Jaerve and Mu¨ller, 2012; Bellavance
and Rivest, 2012; Akiyama et al., 2000). For the purpose of this
Review, we will discuss two major cytokines with radically
different purposes: IL-1b and TGFb. IL-1b is a powerful proin-
flammatory cytokine produced in response to TLR activation in
a Myd88-dependent manner, playing a key role in the early
stages of innate immune reaction (Herx et al., 2000). After TLR
activation and NF-kB induction, IL-1b is produced at the NVU
by microglia, cerebral endothelial cells, and astrocytes (Soulet
and Rivest, 2008b) as an inactive protein that is proteolytically
processed by the inflammasome to generate its active form
(John et al., 2005). IL-1b binds and activates its receptor com-
plex formed by IL-1 receptor type I (IL-1RI) and IL-1RI accessory
protein (IL-1RAP) (Steinman, 2013), leading to NF-kB and acti-
vating protein-1 (AP-1) nuclear translocation and higher intracel-
lular calcium concentration (Spo¨rri et al., 2001). IL-1RI is present
on the surface of cerebral endothelial cells, astrocytes, neurons,
and microglia (Srinivasan et al., 2004; Van Dam et al., 1996).
Recently, an isoform of the IL-1RAP specific to the CNS was
discovered, further defining the link between inflammation and
neuronal survival (Smith et al., 2009). For decades, research on
IL-1b has focused on its detrimental effects in neuroinflammation
(Friedlander et al., 1997). Recent studies reported new protective
and regenerative functions of this cytokine in several CNS
disease models, by mainly enhancing the production of insulin-
like growth factor-1, ciliary neurotrophic factor, and NGF by
astrocytes and microglia (Mason et al., 2001; Herx et al., 2000;
DeKosky et al., 1996). In parallel, IL-1b signaling seems to
have a major role in BBB functions, as it has been shown to
modulate BBB physical permeability and potentially enhanced
immune cell infiltration into CNS (Argaw et al., 2006).
TGFb is a multifunctional cytokine involved in immunosup-
pression and the control of cellular proliferation and extracellular
matrix (ECM) production. Members of this family are produced
as inactive precursors that are maturated in the trans-golgi into
large latent complexes that are released to the ECM. After a
conformational change (controlled by integrins, ROS, pH, and
others), active TGFbs are exposed to their receptor binding
sites. These signal largely through an Smad2/3-dependent
mechanism leading to the recruitment of Smad4 and the induc-
tion of gene expression (Kaminska et al., 2013). TGFb and
TGFb receptor expression has been found in every cell type of
the CNS. It has effects on neuronal survival, microglia migration,
and phagocytosis and has angiogenic potential on cerebral
endothelial cells (Beck and Schachtrup, 2012). Its most docu-
mented effects, however, are carried out in astrocytes by pro-
moting its migration, inhibiting its proliferation, and increasing
the production of ECM components (Kaminska et al., 2013).
Microglia: Powerhouse of the Innate Immune System in
the CNS
Considered tissue-residentmacrophagesmuch likeKupffer cells
for the liver or histiocytes in connective tissues, microglia are the
only cells in the CNS that are of hematopoietic origin (Soulet and
Rivest, 2008b). Fate-mapping analysis has demonstrated that
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before the eighth embryonic day in mice (Ginhoux et al., 2010).
Once present, microglia are capable of self-renewal and do not
require replenishment for circulating monocytic precursors
(Ajami et al., 2007). They are thus distinct from themonocyte line-
age of cells and other tissue-specific macrophages such as
Kuppfer cells in the liver, for which themaintenance is dependent
upon the recruitment of bone marrow-derived cells (BMDCs)
from the circulation (Klein et al., 2007). In the CNS, initial reports
suggested that the recruitment of BMDCs was an active event in
normal physiology (Simard and Rivest, 2004). After an intense
debate on the subject (Soulet and Rivest, 2008a), a consensus
appears to have been reached following new experimental
evidence that BMDC recruitment is a marginal effect in normal
physiology (Lampron et al., 2012) but important in pathological
conditions affecting the integrity of the CNS such as stroke
(Schilling et al., 2009), multiple sclerosis (Floris et al., 2004),
amyotrophic lateral sclerosis (Vaknin et al., 2011), and others.
This recruitment can be beneficial or harmful, depending on the
condition studied (Shechter and Schwartz, 2013).
In their native state, microglia are highly ramified cells with a
small cellular body. Its extended processes allow microglia to
rapidly sense the presence of tissue damages or signs of infec-
tions through PRRs. Microglia are highly plastic cells, they
respond rapidly to the danger signals released by injured cells
and secrete appropriate cytokines both to clear debris and to
attract other microglial cells (Soulet and Rivest, 2008b). They
are specialized cells that respond to specific stimuli in a much
more specific and ordered manner than was previously thought.
To simplify the concept ofmicroglial response, a dichotomy in the
activation states of microglia was suggested. Based on the Th1/
Th2 and M1/M2 activation states of T cells and macrophages,
respectively, two basic states were suggested for microglia,
mostly dependent upon the nature of the stimulus. In theM1 acti-
vation state, also coined the classically activated or proinflam-
matory state and modeled in vitro by LPS stimulations, microglia
show high levels of Ly6C expression and will secrete proinflam-
matory cytokines such as IL-1b and TNF-a and have a high
phagocytosis and proteolysis potential (Martinez et al., 2008).
Through the release of iNOS and ROS, M1 monocytes are tuned
for the clearance of bacterial infections. In the M2 state, also
called the alternatively activated or tissue repair state and
modeled in vitro by IL-4 or IL-10, microglia show lower levels of
Ly6C expression and are geared toward tissue repair through
the production of VEGF, chemokines, and extracellular matrix
proteins (Boche et al., 2013). However, in vitro experiments sug-
gest that the polarization of microglia is a much more complex
concept as each set of stimuli leads to the expression of specific
proteins. For example, IL-4 and IL-10both induce anM2state but
IL-4-stimulated microglia will be biased toward the killing and
encapsulation of parasites, with high levels of arginase 1 expres-
sion, whereas IL-10-stimulated microglia show high potential of
tissue remodeling with low levels of arginase 1 (Banchereau
et al., 2012). This led some investigators to further dissect the
M2 state into three separate states (M2a, M2b, and M2c) (Marti-
nez et al., 2008). Most of the work on this polarization effect has
been done in vitro, stimulating isolated microglia with a single
stimulant such as LPS or IL-4. However, microglia are underthe control of a complex network of PRRs leading to specific
responses to a given stimulus both at the membrane by TLRs
and in the cytoplasm byNLRs and RLRs (Figure 2). In the context
of bacterial infection, for example, microglial cells are activated
not only by proteoglycans from the cell walls but also by bacterial
DNA, ATP, and other components of the bacteria. If we add to
this the crosstalk between astrocytes, neurons, and microglia,
each responding to the insult in their own way, we understand
that limiting the activation state of microglia to only two basic
steps might be a too simplistic view to reflect the complex
response mounted in the CNS against a given insult. While the
M1/M2 paradigm facilitates a discussion on a broad view of the
role of microglia in a given situation, we suggest using more spe-
cific terms such asMS-polarizedmicroglia inmultiple sclerosis or
AD-polarized microglia in Alzheimer’s disease, for example.
The Neurovascular Unit: Cells of the Innate Immune
System
The tight coordination between neuronal and cerebrovascular
functions is a prerequisite for a proper function of the CNS.
Neuronal and BBB functions are tightly associated. Neurons,
directly or indirectly via astrocyte processes, control BBB’s
functions based on their activity requirements (Koehler et al.,
2009). This coordination gives rise to an essential concept in
understanding the physiology of the CNS: the NVU (Hermann
and Elali, 2012). The NVU represents cell-cell interactions, cross-
talk, and signaling that are crucial and essential for proper
functions of neurons. As such, it is conceivable that the NVU
constitutes a dynamic interface contributing actively in CNS
innate immunity. The importance of the NVU in the context of
innate immunity relies on two main aspects: (1) the well-estab-
lished roles of microglia, astrocytes, and the recently emerging
roles of endothelial cells and pericytes in the innate immune
responses and (2) the production of bioactive molecules upon
the induction of innate immunity in the CNS by these cells,
among which are several molecules that can potently modulate
the functions of the BBB and consequently modulate immune
responses of the CNS.
Endothelial Cells
Endothelial cells link peripheral immune responses to the CNS
by acting as mediators and sensors of immune processes in
the periphery. Due to their location at the luminal side of the
BBB, endothelial cells are in continuous contact and crosstalk
with blood circulation and are therefore under continuous chal-
lenges. Endothelial cells are considered the first line of defense,
and recent data demonstrated an active role of these cells in
innate immunity in the CNS (Danese et al., 2007). Under physio-
logical conditions, endothelial cells are immunologically quies-
cent, which is translated by downregulation of proinflammatory
mediators and basal expression of adhesion molecules (Alvarez
et al., 2011). TLRs’ and NODs’ expression and functionality are
well documented in peripheral endothelial cells (Danese et al.,
2007). In cerebral endothelial cells, functional levels of TLR2/3/
4/6 and TLR9 have been reported (Nagyoszi et al., 2010;
Constantin et al., 2004). TLR2/6-specific stimulation in cerebral
endothelial cells triggers ERK1/2 signaling pathway, inhibiting
the expression of TJ proteins, thereby increasing endothelial
paracellular permeability (Nagyoszi et al., 2010). Interestingly, itNeuron 78, April 24, 2013 ª2013 Elsevier Inc. 219
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(MCP-1, i.e., CCL2) and regulated and normal T cell expressed
and secreted (RANTES, i.e., CCL5) can induce TLR2/6 activation
during innate immune reactions upon immunization against res-
piratory syncytial virus (Murawski et al., 2010). This observation
would suggest that CCL2 and CCL5 can trigger TLR2/6 activa-
tion, which enhances cerebral endothelial cell paracellular
permeability, delineating a possible coordination and crosstalk
between monocytes and leukocytes with the BBB during neuro-
inflammatory process.
Tight and excessive adherence of immune cells to cerebral
endothelium via adhesion molecules is mandatory for immune
cells to successfully enter CNS parenchyma. Under normal
conditions, cerebral endothelial cells exhibit basal expression
of adhesion molecules. Once endothelial cells sense the pres-
ence of an immunological threat, they produce proinflammatory
mediators, such as IL-1b (Creagh and O’Neill, 2006), and
surface-specific adhesion molecules, such as intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), and E-selectin-1 (ELAM-1) (Dinarello, 2009). Immune
cells use these adhesion molecules to migrate across cerebral
endothelial cells mainly by loosening TJ contacts. For example,
ICAM-1 crosslinks the lymphocyte function-associated anti-
gen-1 (LFA-1) and induces downstream signaling pathway lead-
ing to cytoskeleton reorganization in cerebral endothelial cells
and loosens TJs, thus facilitating leukocytes and B cell paracel-
lular transmigration (Etienne-Manneville et al., 2000). Moreover,
the IL-1b-induced expression of ICAM-1 has been shown to
enhance neutrophil infiltration into CNS across cerebral endo-
thelial cells (Stanimirovic et al., 1997). Furthermore, some trans-
porters of the cerebral endothelium are targets of innate immune
responses. ABC transporters play an important role in innate
immunity, as it has been shown that inhibiting ABCB1 or
ABCC1 on astrocytes reduced chemokine C-C motif ligand-2
(CCL2) release from these cells, resulting in decreased migration
of monocytes across an in vitro model BBB (Kooij et al., 2011). In
parallel, several proinflammatory molecules are substrates of
ABC transporters, implicating the latter directly in the immune
response. For instance, ABCB1 has been shown to be involved
in transporting the platelet-activating factor (PAF), steroids,
and sphingosine-1-phosphate (S1P) (Honig et al., 2003; Rao
et al., 1994; Raggers et al., 2001). In addition, systemic inflam-
mation may affect the BBB function even before extravasation
of immune cells. Such a response increases the production of
proinflammatory cytokines in blood circulation, which can bindFigure 3. Communication between the CNS and Its Environment at the
The communication between the CNS and the environment is a critical part of an in
from the CNS into the circulation (A, inside-out) and from the circulation into the
(A) The inside-out model. The stimulation of PRRs by pathogens or by toxic mo
mokines, and growth factors. Among them, TNFa and IL-1b activate cytokine rec
loosening, the upregulation of adhesion molecule, such as ICAM-1, E-selectin, a
receptors expressed on the surface of astrocytes and pericytes, inducing further
latter. CCL2 can be transported to the luminal side of the BBB by ABCB1 expres
(B) The outside-in model. The binding of pathogen molecules and proinflammato
deregulation and the upregulation of adhesion molecules, such as ICAM-1, E
adhesion molecules increases adhesion of leukocytes to the luminal side of the
skeleton reorganization and TJ loosening, creating a gap between endothelial ce
cross the BBB. Infiltrating leukocytes and pathogens trigger the activation of o
production of several cytokines, chemokines, and growth factors, such as TNFato their respective receptors on the surface of brain endothelial
cells (Schiltz and Sawchenko, 2002). This leads to the activation
of enzymes (i.e., cyclooxygenase-2, nitric oxide synthase, etc.)
and the production of bioactive molecules that have the ability
to modulate BBB integrity (Laflamme et al., 1999; Schiltz and
Sawchenko, 2002), therefore facilitating the subsequent migra-
tion of immune cells into the brain parenchyma. Finally, the
expression of several ABC transporters has been demonstrated
to dramatically change once endothelial cells are exposed to the
proinflammatory cytokine TNF and IL-1 (Figure 3).
Pericytes
CNS pericytes belong to the lineage of vascular smooth muscle
cells (vSMCs) and are physically the closest cells to CNS endo-
thelial cells, forming peg-and-socket structures around them
(Armulik et al., 2011). Pericytes cover up to 30% of endothelial
layer circumference and play an important role in regulating
endothelial cell proliferation, survival, migration, and cerebrovas-
cular branching (Hellstro¨m et al., 2001). Pericytes are packed at
the abluminal side of cerebral endothelial cells, controlling endo-
thelial functions, and therefore play a central role in integrating
luminal signals generated from cerebral endothelial cells to
CNS parenchyma (Hermann and Elali, 2012). Recent reports
have shown that pericytes play an important role in CNS immu-
nity at many levels. Being contractile cells, dysfunction of these
cells reduces CNS microcirculation, deregulating regional cere-
bral blood flow (rCBF), which takes place before immune reac-
tion (Ferna´ndez-Klett et al., 2010; Bell et al., 2010). Nitrosative
stress induced by initiation of the innate immune response has
a deep impact on pericyte functions by inducing continuous
contraction, which results in blood entrapment in CNS capillary
beds (Yemisci et al., 2009), exacerbating the local immune re-
sponses. Moreover, numerous studies have outlined a possible
function of pericytes as macrophages in the CNS based on the
presence of a high number of lysosomes within their cytoplasm
(Xiong et al., 2009), their efficient capacity of internalizing tracers
injected in blood circulation, and cerebrospinal fluid (CSF)
(Rucker et al., 2000), along with a potential for phagocytosis
(Balabanov et al., 1996) and antigen presentation capacities
(Hickey and Kimura, 1988). Pericytes isolated from lung and
CNS vasculature express functional TLR4, the activation of
which regulated endothelial function and affected vascular
permeability (Edelman et al., 2007; Balabanov et al., 1996).
Moreover, some studies showed that, while quiescent under
physiological conditions, pericytes are capable of inducing their
macrophage-like activity after TLR4 signaling induction (GraeberNeurovascular Unit
nate immune response. This communication is effective in both directions, i.e.,
CNS (B, outside-in).
lecules in the CNS induces the production of a wide range of cytokines, che-
eptors expressed at the abluminal side of brain endothelial cells, leading to TJ
nd P-selectin, and BBB opening. Moreover, TNFa and IL-1b activate cytokine
production of CCL2 by the former and enhanced phagocytosis activity by the
sed on endothelial cells exacerbating infiltration of leukocytes and monocytes.
ry cytokines to their receptors expressed on brain endothelial cells causes TJ
-selectin, and P-selectin. The enhanced and prolonged expression of these
BBB. The crosslink between LFA1 and ICAM-1 induces endothelial cell cyto-
lls, through which leukocytes and pathogens present in blood circulation can
ther PRRs expressed on microglia, astrocytes, and pericytes, leading to the
, IL-1b, CCL2, and GM-CSF.
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cytes produce immune-active molecules, such as nitric oxide
(NO), and a wide range of cytokines and chemokines, namely
granulocyte-colony stimulating factor (G-CSF), granulocyte
macrophage-colony stimulating factor (GM-CSF), CCL3, and
CCL4 (Kovac et al., 2011) (Figure 3).
Recently, pericytes have been given special attention for
their roles in neurodegenerative diseases, namely AD. Pericytes
induce BBB formation, mainly by downregulating genes associ-
ated with vascular permeability (Daneman et al., 2010) and
inducing the activity of ABCB1 in brain endothelial cells (Al
Ahmad et al., 2011). Loss of pericytes has been proposed to
initiate the pathogenesis of neurodegenerative diseases by
causing a primary cerebral vascular injury (Winkler et al., 2011).
Consequently, the primary vascular injury leads to the extravasa-
tion of blood-borne molecules into brain parenchyma, leading to
neuronal death (Winkler et al., 2011).
Perivascular Space
Both pericytes and endothelial cells are ensheathed by the basal
lamina, which is composed mainly of ECM proteins, such as
collagen type IV, heparin sulfate proteoglycans, laminin, and
fibronectin (Farkas and Luiten, 2001), that constitutes the peri-
vascular space and provides a physical support for endothelial
cells and pericytes. Besides providing physical support, the
perivascular space acts as a backup immune surveillance and
scavenging center by constituting a niche for several immune
cells that patrol CNS vasculature, namely perivascular microglia
(Bechmann et al., 2001). The origin of perivascular microglia is
not fully elucidated, but it is widely accepted now that they
originate from the monocyte/macrophage lineage and are
continuously and rapidly replaced by blood circulating bone
marrow-derived cells (Gehrmann et al., 1995; Bechmann et al.,
2001). Although perivascular microglia perform normal microglial
functions, they are different due to their interaction and crosstalk
with cerebral endothelial cells. For instance, they have been
shown to play a major role in supporting vascular integrity and
repair (Ritter et al., 2006). Perivascular space creates a special
milieu that controls the behavior and fate of infiltrated immune
cells. This has been unraveled by the presence of newly differen-
tiated dendritic cells from a subset of CD14+ infiltrated mono-
cytes when exposed to high concentrations of TGFb and
GM-CSF (Ifergan et al., 2008). Moreover, fibrinogen leakage
and accumulation in the perivascular space have been shown
to induce early perivascular microglial clustering toward CNS
vasculature (Davalos et al., 2012).
Astrocytes
Astrocyte endfeet ensheathe more than 90% of brain capillaries,
and this interaction is crucial and essential in the function of the
BBB. Astrocytes also act as scaffold cells by guiding neurons
during development (Jacobs andDoering, 2010) and by orienting
newly formedbrain capillaries (Bozoyanet al., 2012).Under phys-
iological conditions, astrocytes communicate physically with the
endothelium through ECM proteins that act as ligands for adhe-
sion receptors, namely the integrin and dystroglycan that bridge
astrocyte endfeet to endothelial cells (del Zoppo and Milner,
2006). They are characterized by their capacity to produce and
secrete awide rangeof bioactivemolecules that control endothe-
lial function, such as VEGF, TGFb, bFGF, TNFa, IL-1b, IL-3, IL-6,222 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.Ang-1, B cell-activating factor (BAFF), and glial-derived neurotro-
phic factor (GDNF) (Igarashi et al., 1999; Chung and Benveniste,
1990; Farina et al., 2007; Abbott et al., 2006). These play a crucial
role in innate immune responses. Astrocytes have been shown
to express TLR2/3/4/5/9 and NOD1/2 and can produce TNFa
when stimulated with LPS (Chung and Benveniste, 1990). Astro-
cytes act like an assistance and maintenance agent of innate
immunity by supporting and orienting the beneficial effects of
innate immune responses. This role of astrocyteswashighlighted
by using a mouse model of nonfunctional astrocytes, in which
they have been shown to play a crucial role in controlling the
immune responses, mediating BBB maintenance, and support-
ing neuronal survival and functions (Bush et al., 1999).
Innate Immunity in Diseases of the CNS
Innate immunity reacts to all kinds of attacks on CNS integrity.
These can be divided into four main groups: acute injuries
(mechanical traumas, ischemic stroke, etc.), neurodegenerative
chronic diseases (Alzheimer’s disease, multiple sclerosis, etc.),
brain tumors (glioblastomas), and infections (HIV, E. coli, etc.).
While there is a lot to discuss regarding the role of innate
immunity in infection, stroke, and brain tumors, we will focus
this part of the discussion on the implication of the innate
immune system in two chronic diseases: Alzheimer’s disease
and multiple sclerosis. We will use these complex pathological
states to highlight the integration of all cell types of the NVU
and how they can be used efficiently to develop new compre-
hensive ways of targeting such diseases.
Alzheimer’s Disease
Alzheimer’s disease is caused mainly by the deposition of
Ab into plaques in the CNS. The innate immune system plays a
role in the development of the pathology as chronic exposure
ofmicroglia to Ab leads to uncontrolled inflammation, the release
of toxic free radicals, and reactive oxygen species, as originally
described in postmortem studies (Uchihara et al., 1997;
Cagnin et al., 2001). Furthermore, large scale genome-wide
association studies (GWAS) of thousands of AD subjects have
shown that among the ten genetic polymorphisms most tightly
linked to the development of late onset AD, nine play a dominant
role in immunological processes (Moraes et al., 2012). In the
serum, cerebrospinal fluid, and the cortex of affected patients,
higher levels of IL-1b, IL-6, TNFa, IL-8, and TGFb have all been
reported (for in-depth Reviews, see Rubio-Perez and Morillas-
Ruiz, 2012 and Akiyama et al., 2000). Similarly, both TLR2 and
TLR4 are overexpressed in peripheral blood mononuclear cells
from patients with AD (Zhang et al., 2012). It also appears that
the main monocytic chemoattractant CCR2 and its ligand
CCL2 are involved in the progression of AD (Naert and Rivest,
2011; Conductier et al., 2010; Westin et al., 2012). Furthermore,
while no genetic association at the TLR4 locus was found in
GWAS for AD (Moraes et al., 2012), polymorphisms in the
TLR4 gene were shown to increase the incidence of late-onset
AD in populations from Italy (Balistreri et al., 2008; Minoretti
et al., 2006) and China (Wang et al., 2011; Yu et al., 2012;
Chen et al., 2012). The reported data on humans state that, in
essence, AD is first and foremost an immunological disease.
The main genetic risk factor identified in GWAS for late-onset
AD is ApoE4 (Bettens et al., 2013). The family of Apolipoprotein E
Figure 4. Roles of Innate Immunity in the
Development of Alzheimer’s Disease and
the Beneficial Effects of M-CSF as a
Therapeutic Strategy
While the pathological hallmark of AD remains Ab
plaques and deposits, impaired microglial func-
tions and a defect in monocytic cells seem to play
amajor role in the progression of the disease. They
contribute to the increased Ab levels inside the
CNS through inefficient clearance of circulating Ab
and through ill-controlled inflammatory mecha-
nisms leading to inefficient clearance of cerebral
Ab deposits. These act in synergy to skew the sink
effect in the wrong direction, leading to important
Ab deposition, neurodegeneration, and ultimately
cognitive decline. M-CSF has shown great prom-
ises as a therapeutic strategy for AD in animal
models and clinical data in humans suggest that
this molecule could prove efficient in the preven-
tion of Ab deposits. Such a treatment regulates the
count and function of circulating monocytes but
also restores microglial function for an efficient
clearance of Ab. If successful, these effects
restore a positive sink effect of Ab outside of the
CNS and would lead to cognitive improvement.
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lipids, mainly by the binding of LDLRs and LRPs (Mahley, 1988;
Holtzman et al., 2012). Humans have three common alleles of
apoE gene, apoEε2, apoEε3, and apoEε4, which give rise to
three protein isoforms, ApoE2, ApoE3, and ApoE4 (Bell et al.,
2012). Biochemical studies have shown that ApoE4 has very
weak affinity to its receptors and does not induce any signaling
activity, whereas ApoE3 has very high affinity to its receptors
and induces the activation of several signaling pathways down-
stream to its receptors (ElAli and Hermann, 2010). ApoE has high
expression levels in the brain, is produced mainly by astrocytes,
and has been shown to have protective roles at the CNS (Holtz-
man et al., 2012; Mahley, 1988). It is a prime example of the
importance of the NVU concept, integrating most cells present
in the CNS. In addition to its role in cholesterol and lipid trans-
port, ApoE has many other physiological and pathophysiological
functions within the CNS (Holtzman et al., 2012). ApoE signaling
pathway within the NVU constitutes the mediator that integrates
the functions of different cells forming the NVU, therefore playing
key roles in modulating BBB functions (Bell et al., 2012; ElAli and
Hermann, 2010). More precisely, ApoE4 can alter the BBB by the
formation of the cyclophilin A (CypA)/NF-kB complex in peri-
cytes and matrix metalloproteinase-9 (MMP-9) production in
the perivascular space, which may lead to ECM degradation.
Interestingly, ApoE3 was able to reverse these detrimental
effects of APoE4 (Bell et al., 2012). Moreover, ApoE is able
to bind ApoE receptor 2 (LRP-8) on the surface of cerebral
endothelial cells, which abolishes c-Jun phosphorylation and
increases the expression of ABCB1 in the luminal side of the
BBB (ElAli and Hermann, 2010). ApoE may also act as endoge-
nous immunomodulatory molecules for both innate and adaptive
immunities in the CNS (Terkeltaub et al., 1991; Pepe and Curtiss,
1986).
Whether the activation of the innate immune system is a cause
or a consequence of the development of AD is still highly
debated. In vitro studies showed that fibrillar Ab acts directlyon microglia, activating TLR4 and TLR2 and the release of
TNFa that leads to neuronal death, as demonstrated inmicroglial
cell lines and microglia neuron coculture (Reed-Geaghan et al.,
2009; Udan et al., 2008; Stewart et al., 2010). On the other
hand, in vivo studies in mouse models depict another picture.
Knockouts or genetic inactivation of TLR4 (Tahara et al., 2006;
Song et al., 2011), TLR2 (Richard et al., 2008), Myd88 (Michaud
et al., 2011), or TNFa receptors (Montgomery et al., 2011) in
mouse models of AD have all aggravated the symptoms of the
disease, including cognitive functions and amyloid deposition.
These differences have led to a better understanding of inflam-
matory processes in AD. For multiple reasons (genetic predispo-
sition, ineffective clearance, previous injuries, etc.), Ab starts
to accumulate in the CNS into toxic oligomers and plaques.
These are detected by microglia as DAMPs, activating a
TLR2/4 response. Although microglia can be effective to clear
Ab in vitro (Reed-Geaghan et al., 2009), they alone cannot
resolve the injury in vivo, as Ab production surpasses microglia’s
capacity for its clearance. Microglial cells then enter a nonresolv-
ing chronic inflammatory circle of continuous inefficient activa-
tion, thus contributing to disease progression, a process we
like to call ‘‘frustrated inflammation’’ (Figure 4).
The innate immune system, however, does possess a capacity
for the clearance of Ab and can play a beneficial role in AD. This
would explain the detrimental effects of knocking out completely
the innate immune response, while beneficial effects of inhibiting
selective parts of it can prove to be an efficient therapeutic strat-
egy. This was highlighted by the failure of nonsteroidogenic anti-
inflammatory drugs (NSAIDs) to treat AD in large-scale clinical
trials (Imbimbo, 2009). Initial reports have shown that subjects
on recurring treatments of NSAIDs had lower incidence of AD
(McGeer et al., 1996). The reason for the clinical failure was
that it had been forgotten why the subjects on NSAIDs needed
to receive these drugs in the first place: they have an overly
active innate immune system that was helping prevent the
development of AD. As such, a tightly regulated stimulation ofNeuron 78, April 24, 2013 ª2013 Elsevier Inc. 223
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another way of designing new treatment options for AD. This
can be achieved with the use of novel TLR ligands that can stim-
ulate the clearance of Ab without inducing overt inflammatory
processes. We have recently demonstrated the beneficial ef-
fects of monophosphoryl lipid A (MPL) in mouse models of AD
(Michaud et al., 2013). MPL, a detoxified TLR4 ligand, induced
a high phagocytic potential in microglia, as much as LPS, while
showing almost undetectable production of inflammatory cyto-
kines or ROS. In AD mouse models, a chronic treatment with
MPL reduced Ab production by up to 80% in some cases and
normalized their cognitive behavior. This paves the way for the
development of safe immunomodulatory therapies in AD as a
monotherapy but also as complements to other Ab-lowering
strategies such as vaccination.
Although most of the work in AD has focused on neurodegen-
eration and inflammatory processes, accumulating evidence
shows that a dysregulation of the vasculature is just as important
in the development of AD (Zlokovic, 2011). Most of the work on
the implication of innate immunity in AD has focused on the
role of microglia. However, novel exciting research shows that
the rest of the NVU is a prime candidate for the creation of
new therapeutic strategies for AD. Pioneer work from the team
of Zlokovic has shown that LRP-1, a specific transporter at the
BBB, is critical in the clearance of Ab from the CNS into the
circulation (Deane et al., 2004). In further studies, the authors
found that LRP-1 was upregulated upon LPS stimulation, there-
fore presumably enhancing pericytes and endothelial cells’
capacity to internalize the toxic peptide Aß given the major role
of LRP-1 in Aß processing (Deane et al., 2008). Moreover,
ABCB1 and ABCG2 have been shown to be involved in the elim-
ination of Ab from the CNS (Xiong et al., 2009; Cirrito et al., 2005;
van Assema et al., 2012). In the other direction, the receptor for
advanced glycation endproducts (RAGE) controls the transfer of
Ab from the circulation into the CNS, either directly (Deane et al.,
2003) or by facilitating the entry of Ab-laden monocytes into the
CNS, thereby contributing to the development of the disease and
another suitable target for treatment (Deane et al., 2012). We
understand now that the levels of Ab in the brain are an equilib-
rium between its production and its clearance, reflected at the
BBB as a balance between its entry and its exit from the CNS
through the LRP-1/RAGE tandem. These results have helped
develop the hypothesis that clearing Aß in the circulation could
create a vacuum that pulls the Aß from the CNS into the circula-
tion through these transporters. This so-called ‘‘sink hypothesis’’
warrants the targeting of the periphery to have positive effects in
the CNS. One such compound is the macrophage-colony stim-
ulating factor (M-CSF), the main growth factor for cells of the
monocytic lineage (Hume and MacDonald, 2012) (Figure 4).
Injecting M-CSF to transgenic mice that spontaneously develop
AD on a weekly basis prior to the appearance of learning and
memory deficits prevented cognitive loss. The treatment also
restored the population of M1 monocytes in the circulation and
greatly decreased Ab levels. In addition, M-CSF treatment
resulted in the stabilization of the cognitive decline state in trans-
genic mice that already had Ab pathology (Boissonneault et al.,
2009). In vitro, exposure of mouse microglia to M-CSF enables
the acidification of their lysosomes and, subsequently, the224 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.degradation of internalized Ab (Majumdar et al., 2007). In this
regard, low levels of M-CSF were recently measured in patients
with presymptomatic AD or mild cognitive impairment, which
together with low levels of other hematopoietic cytokines pre-
dicted the rapid evolution of the disease toward a dementia diag-
nosis 2 to 6 years later (Ray et al., 2007). This is one of the ways
the hematopoietic system can be used to treat AD (Lampron
et al., 2011).
Multiple Sclerosis
Multiple sclerosis is a chronic neuroinflammatory CNS disorder
with a widespread degradation of the myelin sheaths of axons.
It is characterized by focal lymphocyte infiltration into CNS
parenchyma, which is associated with BBB dysfunction and
microglia activation (Cristante et al., 2013; Compston and Coles,
2008). During the early stages of MS pathogenesis, the insults
triggered by infiltrated lymphocytes are transient and both
demyelination and neurological dysfunction are reversible. This
is the relapsing-remitting phase of the disease. With time, the
pathogenesis evolves to reach exacerbated inflammation,
irreversible demyelination, and permanent neurological dysfunc-
tions, leading to the formation of demyelinated plaques in the
CNS, the progressive stage of the disease (Compston and
Coles, 2008). The early factors involved in MS pathogenesis
are still largely unknown. However, lymphocyte infiltration, and
its interaction with antigen-presenting cells of the CNS (mostly
microglia), is seen as the crucial step in the early stages of MS
pathogenesis (Minagar and Alexander, 2003). Although myelin-
reactive T cells have been shown to be the most important
infiltrates, recent data demonstrated an important role for B cells
in the pathogenesis of MS, characterized by their specific proin-
flammatory polarization (von Bu¨dingen et al., 2012). As such, the
mechanisms by which T and B cells migrate through endothelial
cells are key steps in the pathogenesis of MS and a prime target
for novel therapeutic strategies.
At the molecular level, the local production of proinflammatory
molecules such as TNF-a and IL-1b leads to elevated expression
of adhesion molecules ICAM-1 and VCAM-1 (Dore-Duffy et al.,
1993; Maimone et al., 1991) and chemokines such as CCL2,
CCL5, and CCL3 (Prat et al., 2002). These effects contribute to
the recruitment and the attachment of circulating lymphocytes
to the BBB. Lymphocytesmigrate using twomain routes. A para-
cellular route involves LFA-1/ICAM signaling that results in
cytoskeleton reorganization and TJ opening leading to cellular
infiltration. A transendothelial route involves the interaction
between ICAM-1 and caveolae on inflamed endothelial cells
inducing the formation of vesiculo-vacuolar organelles that
create an intracellular duct through which leukocytes can
migrate (Ley et al., 2007). The contribution of the immune
responses at the NVU was further highlighted by showing the
capacity of astrocytes to produce and secrete CCL2, which
enhanced both monocyte and leukocyte migration through the
BBB (Weiss et al., 1998). In humans, MRI techniques have re-
vealed a positive correlation between MS active lesions, BBB
permeability, perivascular cuffs (cerebral capillaries surrounded
by plaques), and massive infiltration of monocytes (Minagar and
Alexander, 2003). BBB dysfunction is also a factor in experi-
mental autoimmune encephalomyelitis (EAE), a widely used
animal model of MS (Floris et al., 2004). We have mentioned
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cytokines and adhesion molecules, thereby augmenting the
recruitment and infiltration of T cells. In addition, the presence
of an inflammatory microenvironment at the NVU has been
shown to play a crucial role in deciding the fate of infiltrated
monocytes across the BBB bymediating the differentiation of in-
filtrated monocytes into dendritic cells that have been reported
to be abundant in the perivascular space of MS lesions (Ifergan
et al., 2008). Numerous studies have also shown that microglial
TLRs are upregulated in MS and EAE (Olson and Miller, 2004).
The contribution of the innate immune response was further out-
lined by the resistance of TLR4/9- and Myd88-deficient mice to
EAE induction (Marta et al., 2009). The exact role of astrocytes in
MS is still debated. A recent study has shown that inducing an
MS-like pathology in mice whose astrocyte population had
been depleted does not prevent damages to the myelin sheaths.
However, the clearance of damaged myelin by microglia was
impaired, as astrocytes were not able to recruit phagocytic
microglia to the damaged myelin, impeding oligodendrocytes
to remyelinate the axons (Skripuletz et al., 2013). This study
illustrates the point that while inflammatory innate immune pro-
cesses are clearly detrimental in the pathophysiology of MS,
astrocytes and microglia also have crucial functions limiting
the progression of the disease.
Within the NVU, MMPs play an important role in immunomo-
dulation. Indeed, MMP-9 levels and activity have been shown
to increase in MS lesions, CSF, and the plasma of MS patients
(Fernandes et al., 2012; Leppert et al., 1998; Lindberg et al.,
2001). MMP-9 contributes in the pathogenesis of MS/EAE by
acting as a mediator of leukocyte infiltration into the CNS, espe-
cially the proinflammatory T helper 1 (Th1) CD4+ lymphocytes
(Abraham et al., 2005). MMP-9 specifically induces the degrada-
tion of EMPs, creating ducts within the perivascular space,
which are utilized by lymphocytes in order to invade the CNS
(Agrawal et al., 2006). In addition, MMPs induce the production
of several chemokines and cytokines within the NVU structure,
which deeply affect the migration and infiltration of immune cells
into the CNS (Larochelle et al., 2011). In MS and EAE, MMPs
are mainly produced by activated lymphocytes and macro-
phages by specifically inducing the extracellular MMP inducer
(EMMPRIN) factor (Agrawal and Yong, 2011). Interestingly,
targeting EMMPRIN with a neutralizing antibody specifically
decreased MMP-9 activity within lesion sites and consequently
decreased leukocyte infiltration, which attenuated in EAE
severity (Agrawal et al., 2011).
After three decades of advancement in the field, numerous
therapeutic options have been developed for MS, including
immunomodulators such as interferon-b, glatiramar acetate,
and mitoxantrone. While these are effective in reducing the fre-
quency of relapses, none of them can reverse the progression
of the disease (Polman and Uitdehaag, 2003; Wiendl and
Hohlfeld, 2009), highlighting the need for the development of
new therapeutic approaches for MS. Although the contribution
ofmicroglial cells inMS and EAE pathogenesis has been outlined
as being detrimental, new emerging reports shed the light on a
protective role for these cells in the context of MS and EAE,
mainly by producing anti-inflammatory cytokines, such as IL-
10 and TGF-b, and by acting as scavengers to eliminate toxicdebris present in lesion sites, responses that seem to be depen-
dent on the local inflammatory microenvironment (Napoli and
Neumann, 2010). Moreover, it was reported that Heat-shock
protein 70 (Hsp70), an endogenous ligand of TLR2/4 present
on microglia, is overexpressed in MS and EAE, which was sug-
gested as a possible neuroprotective process triggered by neu-
rons to rescue the systemdue to Hsp70’s cytoprotective charac-
teristics. Pharmacological approaches using molecules that
induce and/or stabilize Hsp70 expression have been shown to
ameliorate EAE outcome (Dello Russo et al., 2006). Therefore,
enhancing innate immune responses by Hsp70 induction and
the subsequent activation of TLR2/4 could have beneficial ef-
fects on MS and EAE diseases and advocate for the positive
role of the innate immunity in this context. High-mobility group
box-1 (HMGB-1) is another endogenous TLR2/4 ligand (Maroso
et al., 2010), which seems to play an important role in amplifying
the immune response in EAE and MS (Andersson et al., 2008).
Autologous hematopoietic stem cell transplantation, a radical
approach to target the immune system, has shown great bene-
fits in humans (Burt et al., 2009). The beneficial effects of such
a strategy depend on the formation of a novel tolerant immune
system and/or the long-lasting depletion of immunoreactive
T cells (Gosselin and Rivest, 2011) (Figure 5).
Conclusion and Future Directions
The role played by the innate immune system in brain homeosta-
sis and diseases is becoming one of themost studied subjects in
neuroscience.We andmany other groups have unraveled impor-
tant mechanistic insights, although much remains to be done to
understand how it can be modulated to fight against chronic dis-
eases and help the recovery after injuries. Circulatingmonocytes
are now considered a very important target since they act on the
surface of the NVU to clear toxic proteins, such as soluble Ab,
within the cerebrovascular system. In doing so, they eliminate
critical elements involved in the etiology of Alzheimer’s disease
and new data suggest that novel TLR4 ligands can be used as
therapeutic approaches to stimulate monocytes and other cells
of the NVU (Michaud et al., 2013). The NVU is also critically
involved in the etiology of MS.
The inflammatory response taking place in the CNS has often
been associated with progressive neuronal damage and chronic
brain diseases. However, accumulating evidence now suggests
that CNS-resident microglia and circulating monocytes may
havemore beneficial effects for neurons than previously thought.
It appears likely that monocytic cells and the molecules they
produce contribute to tissue repair and neuronal survival/regen-
eration in certain conditions but become detrimental in other
situations. The apparent discrepancies between the harmful
and beneficial effects of monocytic cells may be due, at least
in part, to the differences in the manner and timing of their
activation and in the way they interact with other cells of the
NVU. Indeed, monocytic cells and other immune cells produce
a different repertoire of cytokines, growth factors, proteases,
free radicals, and other molecules depending on the cell subset
involved and their state of activation that act not only on neurons
but also in every cell of the NVU. As we begin to understand the
molecular determinants that regulate the differentiation, polari-
zation, and activation of these cells toward different phenotypes,Neuron 78, April 24, 2013 ª2013 Elsevier Inc. 225
Figure 5. Harmful Mechanisms of Multiple
Sclerosis and Therapeutic Advantage of
Autologous Hematopoietic Stem Cell
Transplant
MS is a complex chronic disease involving a host
of cells with deregulated roles. The main culprits
are autoreactive T cells specific for the myelin
basic proteins (MBPs), which coat axons for
optimal neuronal transmission. For yet unclear
reasons, these T cells infiltrate massively into the
CNS and induce demyelination leading to
progressive physical and cognitive disabilities.
Monocytic cells (monocytes, macrophages,
microglia, etc.) are also very important in the
development of the disease. Skewed toward a
highly inflammatory activation state, these cells
contribute to the disease by inefficient immuno-
suppression of autoreactive T cells but also by
inducing, or at least not reducing, the infiltration of
T cells into the CNS. Autologous hematopoietic
stem cell transplantation has shown great
promises in the clinic for the treatment of relaps-
ing-remitting MS. Proposed curative mechanisms
of this treatment include the depletion of
autoreactive T cell lineage and the prolonged
immunosuppression of T cells altogether by
chemotherapeutic regimen. Under less stress by
T cells, monocytic cells can now properly function
as neuroprotective and immunosuppressive cells.
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Reviewand the molecular functions of these phenotypes, we will be able
tomake sense of the seemingly contradictory findings on the role
of inflammation in AD and MS.
MS is traditionally considered to be the prototypical autoim-
mune inflammatory disease of the CNS, with a primary immune
assault directed against central myelin antigens and oligoden-
drocytes. The activation of innate immune signaling pathways
in CNS-resident microglia takes place early in the disease pro-
cess, which is followed by a marked recruitment, proliferation,
and activation of monocytes/macrophages in affected regions
of the CNS; these monocytic cells showmost of the characteris-
tics of the M1 subset, characterized by a proinflammatory
phenotype. Activated autoreactive T lymphocytes, including
those of the Th1 and Th17 subsets, are also prominently repre-
sented in MS lesions and interact with monocytic cells to destroy
the myelin. The cause of these abnormal interactions remains
unknown.
AD, however, is not classically described as an inflammatory
disease, but recent evidence suggests that circulating mono-
cytes are key to the disease onset (Malm et al., 2010). It is now
well accepted that key receptors of the innate immune system
are involved in the removal of Ab and may act as a natural
defense mechanism to prevent Ab accumulation in the brain
vascular system and the CNS. The critical question, then, is
why do these receptors fail to remove Ab in the CNS of AD
patients and in mouse models of AD? It is possible that
the phagocytic properties of monocytes and microglia are
decreased with aging and disease progression and/or that the
balance between Ab production and clearance is disturbed in
AD. It has been reported that macrophages of most AD patients
do not transport Ab into endosomes and lysosomes and that
monocyte-derivedmacrophages do not efficiently clear Ab (Fiala
et al., 2005). One possibility is that, in contrast toMS, monocytes
may be polarized toward an anti-inflammatory phenotype (e.g.,226 Neuron 78, April 24, 2013 ª2013 Elsevier Inc.M2) rather than being proinflammatory in AD individuals. In
support of the latter hypothesis is the observation that blocking
signaling by the immunosuppressive cytokine TGFb1 in bone
marrow-derived myeloid cells improved AD-like pathology in
mice (Town et al., 2008). We also found that the progressive
cognitive decline and decrease in expression of numerous syn-
aptic markers and neurotrophins in the brain of AD mice corre-
lated with major changes in the proportions of peripheral blood
monocyte subsets when compared with age-matched controls
(Naert and Rivest, 2012). Indeed, there is a defect in the produc-
tion of circulating M1 monocytes in APP/PS1 mice, whereas the
population of M2 monocytes remains normal in this mouse
model of AD (Naert and Rivest, 2012). Of great interest is that
such a defect in monocyte frequency can be restored by sys-
temic M-CSF treatments (Naert and Rivest, 2012).
The AD/MS paradigm illustrates the complexity of innate
immunity in the CNS, especially when using it as a therapeutic
target for chronic diseases. It is now evident that simple repres-
sion of the whole system in a given disease will not yield enough
results clinically. There is now a need to develop novel integrative
approaches that take into account the role of microglial inflam-
mation, astrocytic processes, the BBB sink, and the interaction
between every cell of the CNS, in order to develop efficient
ways to target such complex pathologies as AD and MS.
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